Genmab A/S GMAB 深 滬
等待開盤 08-14 09:30:00 美东时间
22.5851
+0.715
+3.27%
華盛通- 最 高22.605
- 今 開22.24
- 成交量 54.65万股
- 最 低 22.18
- 昨 收 21.87
- 總市值 138.90亿
- 52周最高 27.94
- 市盈率 靜 12.83
- 換手率 0.09%
- 52周最低 17.235
- 委 比 -14.56%
- 總股本 6.15亿
- 歷史最高 49.07
- 量 比 0.36
- 振 幅 1.94%
- 歷史最低 16.24
- 每 手 1
- 風險率 2.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Genmab Updates Articles to Boost Financial Flexibility
Genmab ( ($GMAB) ) just unveiled an update. On August 13, 2025, Genmab A/S anno...
08-13 22:57
Genmab Announces Capital Increase Following Employee Warrant Exercise
Genmab ( ($GMAB) ) has issued an update. On August 12, 2025, Genmab A/S announc...
08-13 03:27
Genmab Q2 Sales $925.000M Beat $914.759M Estimate
Genmab (NASDAQ:GMAB) reported quarterly sales of $925.000 million which beat the analyst consensus estimate of $914.759 million by 1.12 percent. This is a 18.66 percent increase over sales of $779.514 million the same
08-07 23:17
Genmab Raises FY2025 Sales Guidance from $3.340B-$3.660B to $3.500B-$3.700B vs $3.613B Est
Genmab (NASDAQ:GMAB) raises FY2025 sales outlook from $3.340 billion-$3.660 billion to $3.500 billion-$3.700 billion vs $3.613 billion estimate.
08-07 23:17
Genmab Reports Results Of Phase 3 EPCORE FL-1 Trial Evaluating Subcutaneous Epcoritamab In Combination With Rituximab And Lenalidomide Versus R2 Alone For Treatment Of Adult Patients With R/R FL
Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate (ORR; 95.7%, p < 0.0001) and Progression-Free Survival (HR 0.21, p-value
08-07 22:32
【太平洋医药】板块持续放量，创新产业链和疫苗关注度提升（附4-1BB靶点药物研究）
（来源：市场投研资讯） 本周观点 本周，我们梳理了4-1BB靶点作用机制，重点关注PD-L1/4-1BB的临床进展。 4-1BB是极具潜力的肿瘤治疗靶点，关注...
07-29 10:54
Breaking Down BioNTech: 12 Analysts Share Their Views
BioNTech (NASDAQ:BNTX) underwent analysis by 12 analysts in the last quarter, r...
07-16 20:02
J&J boosts full-year outlook on forex tailwinds and operational performance
Johnson & Johnson (NYSE:JNJ) traded higher in the premarket on Wednesday as the healthcare giant started pharma earnings season, lifting its full-year outlook after reporting better-than-expected fina...
07-16 19:04
Genmab reports Q2 Darzalex net sales of $3.54 billion
Genmab A/S (GMAB) said Wednesday that net sales of Darzalex in the second quarter of 2025 totaled $3,539 million. Net trade sales were $2,017 million in the U.S. and $1,521 million in the rest of the ...
07-16 18:48
Genmab Q2 Worldwide Net Trade Sales Of DARZALEX Totals $3.539B
Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)COPENHAGEN,
07-16 18:32
